TREATMENT OF PAIN USING PLACENTAL STEM CELLS
Provided herein are methods of treatment of an individual having pain, e.g., neuropathic pain, comprising administering to the individual a therapeutically effective amount of tissue culture plastic adherent placental stem cells (PDAC™).
1 . A method of treating pain caused by diabetic neuropathy in an individual, comprising administering to the individual a therapeutically effective amount of placental stem cells, wherein the therapeutically effective amount is an amount sufficient to cause a detectable improvement in said pain.
2 . The method of claim 1 , wherein said method additionally comprises determining one or more first levels of pain caused by diabetic neuropathy in said individual prior to administration of said placental stem cells, and determining one or more second levels of pain caused by diabetic neuropathy in said individual after administration of said placental stem cells, wherein said therapeutically effective amount of placental stem cells reduces said one or more second levels of said pain as compared to said one or more first level of said pain.
3 . The method of claim 2 , wherein said one or more first levels of pain and said one or more second levels of pain are determined by a pain assessment scale.
4 . The method of claim 4 , wherein said pain assessment scale is the Numeric Pain Intensity Scale; the Pain Quality Assessment Scale; the Simple Descriptive Pain Intensity Scale; the Visual Analog Scale; the Wong-Baker FACES Pain Rating Scale; the FLACC scale; the CRIES scale; the COMFORT scale; or evoked pain measure induced by subjecting the patient to cold, heat or mechanical stimuli.
5 . The method of claim 1 , wherein said method additionally comprises determining a first level of one or more physiological indicia of pain caused by diabetic neuropathy in said individual prior to administration of said placental stem cells, and determining a second level of one or more physiological indicia of pain caused by diabetic neuropathy in said individual after administration of said placental stem cells, wherein said therapeutically effective amount of placental stem cells reduces said second level as compared to said first level.
6 . The method of claim 5 , wherein said physiological indicium of pain is heart rate in the individual.
7 . The method of claim 6 , wherein said heart rate in said individual is lower after said administration compared to said heart rate in said individual before said administration.
8 . The method of claim 5 , wherein said physiological indicium of pain is the systolic of said individual.
9 . The method of claim 8 , wherein said systolic of said individual is lower after said administration compared to said systolic in said individual before said administration.
10 . The method of claim 5 , wherein said physiological indicium of pain is the diastolic of said individual.
11 . The method of claim 10 , wherein said diastolic of said individual is lower after said administration compared to said diastolic in said individual before said administration.
12 . The method of claim 1 , wherein said placental stem cells are CD10 + , CD200 + , CD34 − , CD105 + placental stem cells.
13 .- 17 . (canceled)
18 . The method of claim 1 , wherein said placental stem cells express the ELOVL2, ST3GAL6, ST6GALNAC5, and/or SLC12A8 gene at a detectably higher level than an equivalent number of bone marrow-derived mesenchymal stem cells (BM-MSCs).
19 . The method of claim 18 , wherein said placental stem cells additionally express the ARTS-1, IER3, IL6, KRT18, LRAP, MEST, NFE2L3, and/or TGFB2 gene at a detectably higher level than an equivalent number of BM-MSCs.
20 .- 37 . (canceled)
38 . The method of claim 1 , wherein said placental stem cells are formulated to be administered locally, systemically, intravenously or intraarterially.
39 .- 75 . (canceled)